ID   MRK-nu-1
AC   CVCL_1428
SY   MRK-NU-1; Mrk-nu1; MRKnu-1; MRKnu1; MRKNU1
DR   BTO; BTO:0003679
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471641
DR   CCLE; MRKNU1_BREAST
DR   Cell_Model_Passport; SIDM00562
DR   ChEMBL-Cells; CHEMBL3308550
DR   ChEMBL-Targets; CHEMBL2366325
DR   Cosmic; 908151
DR   Cosmic-CLP; 908151
DR   GDSC; 908151
DR   GEO; GSM827236
DR   GEO; GSM1670133
DR   IARC_TP53; 21516
DR   JCRB; JCRB0616
DR   JCRB; JCRB0628
DR   LINCS_LDP; LCL-1487
DR   Wikidata; Q54906738
RX   CelloPub=CLPUB00083;
RX   PubMed=518958;
RX   PubMed=9290701;
RX   PubMed=15900046;
RX   PubMed=20215515;
RX   PubMed=27397505;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: ~47 hours (lot 02072012) (JCRB).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Has no TP53 mutation (PubMed=15900046).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Discontinued: JCRB; JCRB0616; probable.
ST   Source(s): Cosmic-CLP; JCRB
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 8
ST   D16S539: 10
ST   D5S818: 13
ST   D7S820: 8,10
ST   TH01: 6,9
ST   TPOX: 11
ST   vWA: 17,18
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   46Y
CA   Cancer cell line
//
RX   CelloPub=CLPUB00083;
RA   Sekiguchi M., Shiroko Y., Fujii G., Sudo K., Matsuzawa A., Suzuki K.;
RT   "An ascites form of human mammary carcinoma transplantable in nude
RT   mice and isolation of two cell lines cultured in vitro.";
RL   Proc. Jpn. Cancer Assoc. 38:139-139(1979).
//
RX   PubMed=518958;
RA   Sekiguchi M., Sudo K., Suzuki K., Matsuzawa A., Fujii G.;
RT   "An ascites form of human mammary carcinoma transplantable in nude
RT   mice.";
RL   Biomedicine 30:245-249(1979).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=15900046; DOI=10.1093/jnci/dji133;
RA   Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y.,
RA   Yamazaki K., Hamada J., Tada M., Moriuchi T., Ishikawa Y., Kato Y.,
RA   Tomoda H., Yamori T., Tsuruo T.;
RT   "p53-defective tumors with a functional apoptosome-mediated pathway: a
RT   new therapeutic target.";
RL   J. Natl. Cancer Inst. 97:765-777(2005).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//